Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...